Central Nervous System Neoplasms × Temozolomide × Sarcoma × Clear all Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 3 Completed
562 enrolled 11 charts
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Phase 1 Completed
32 enrolled
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Phase 2 Completed
118 enrolled 8 charts
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
Phase 2 Completed
178 enrolled 23 charts
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
70 enrolled 18 charts
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma
Phase NA Terminated
15 enrolled 6 charts
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Phase 1/2 Unknown
50 enrolled
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
122 enrolled 11 charts
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
217 enrolled 12 charts
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
92 enrolled 18 charts
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
Phase 1 Terminated
15 enrolled
TAVAREC
Phase 2 Completed
155 enrolled
Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
Terminated
10 enrolled
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Phase 2 Completed
82 enrolled
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase 1 Completed
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Phase 1 Completed
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
Phase 2 Terminated
15 enrolled
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1 Completed
24 enrolled
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Phase 2 Completed
44 enrolled
Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
32 enrolled
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
Phase 1 Completed
34 enrolled
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Phase 2 Completed
60 enrolled 9 charts
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 2 Completed
110 enrolled
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Phase 1/2 Completed
257 enrolled 16 charts
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
Phase 2 Terminated
12 enrolled 10 charts
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Phase 2 Completed
47 enrolled 7 charts
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Phase 2 Withdrawn
Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1 Completed
45 enrolled
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
Phase 2 Withdrawn
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
Phase 1 Unknown
30 enrolled
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
Phase 1 Unknown
28 enrolled
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Phase 1 Completed
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
170 enrolled
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
Phase 2 Unknown
80 enrolled
Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas
Phase NA Completed
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
Phase 3 Completed
500 enrolled
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Unknown
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Withdrawn
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
Phase 2 Completed
50 enrolled
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Phase 1/2 Completed
30 enrolled
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Phase 1 Completed
Temozolomide in Treating Patients With Recurrent Malignant Glioma
Phase 2 Completed
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
Phase 1 Completed
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Phase 1 Completed
65 enrolled
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Phase 1 Completed
25 enrolled
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
27 enrolled
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 3 Completed
575 enrolled
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
20 enrolled